Lau, David K.
Fong, Caroline
Arouri, Faten
Cortez, Lillian
Katifi, Hannah
Gonzalez-Exposito, Reyes
Razzaq, Muhammad Bilal
Li, Su
Macklin-Doherty, Aislinn
Hernandez, Monica Arenas
Hubank, Michael
Fribbens, Charlotte
Watkins, David
Rao, Sheela
Chau, Ian
Cunningham, David
Starling, Naureen
Article History
Received: 11 January 2023
Accepted: 17 April 2023
First Online: 26 April 2023
Declarations
:
: The study was approved by the Committee for Clinical Research at the Royal Marsden Hospital and informed consent of participant was waived due to retrospective nature of study. The study was conducted in accordance with the principles laid down by the World Medical Assembly in the Declaration of Helsinki.
: Not applicable.
: DL is the recipient of the Australasian Gastro-Intestinal Trials Group/Merck Clinical Research Fellowship. SR has served in a consulting role or on the advisory boards for Bayer, Boehringer Ingelheim, Hookipa Biotech, Incyte and Merck Serono.IC has served in a consulting role or on the advisory boards for Eli Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck Serono, Five Prime Therapeutics, Astra Zeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte, Astellas, GSK, Sotio, Eisai and Daiichi Sankyo; received research funding from Eli Lilly, Janssen-Cilag; and honoraria from Eli Lilly, Eisai and Servier.DC has served in a consulting role or on the advisory boards for OVIBIO; received institutional research funding from 4SC, Bayer, Celgene, Clovis Oncology, Leap Oncology, Eli Lilly, MedImmune, Roche; and has ownership interests in OVIBIO.NS has served in a consulting role or on the advisory boards for AstraZeneca, MSD, Pfizer, Servier; received institutional research funding from AstraZeneca, BMS, Pfizer/ EMD Serono; honoraria from Amgen, GlaxoSmithKline, Lilly, Merck Serono, MSD Oncology, Pierre Fabre, Servier; and travel accommodation expenses from AstraZeneca, BMS, Lilly, Merck, MSD Oncology and Roche. C Fong, FA, LC, HK, RGE, MBR, SL, AMD, MAH, MH, C Fribbens and DW have no disclosures.